Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On April 19, 2023, Aridis Pharmaceuticals, Inc. (the "Company") received written
notice (the "Notice") from the Nasdaq Stock Market, LLC ("Nasdaq") indicating
that Nasdaq had not received the Company's Form 10-K for the year ended December
31, 2022 and this serves as an additional basis for delisting the Company's
securities from The Nasdaq Capital Market. Since the Company already has a
hearing date of May 4, 2023 before the Hearings Panel for its failure to comply
with the $35 million minimum market value of listed securities requirement under
Listing Rule 5550(b)(2), the Company has until April 26, 2023 to request a stay
of the suspension of the Company's securities pending a Hearings Panel decision.
The Company plans to request a stay of the suspension pending the Hearings Panel
decision.
On April 20, 2023, the Company received written notice from Nasdaq that due to
the resignation of Craig Gibbs, Ph.D. from the Company's board and audit
committee on March 27, 2023, the Company no longer complies with Nasdaq's
independent director and audit committee requirements as set forth in Listing
Rule 5605. Pursuant to Nasdaq's cure period, the Company is required to regain
compliance by the earlier of the Company's next annual shareholders' meeting or
March 27, 2024 or if the next annual shareholders' meeting is held before
September 25, 2023, then the Company must evidence compliance no later than
September 25, 2023.
-2-
© Edgar Online, source Glimpses
ARIDIS PHARMACEUTICALS, INC. 
